ARCHIVES

Neratinib Graduates from I-SPY Phase II Adaptive Trial Regimen

This article is from The Cancer Letter archive.

Vol. 37 No. 4 | April 25, 2014

Download PDF Visit The Full Archive

Related Articles

Rejecting Data, Believers In PSA Screening Strengthen Guidelines, Launch Outreach

September 11, 2009

New Community Control Program May Be Developed

October 24, 1975

Palmetto Establishes Coverage For Thyroid Genomic Test

January 27, 2012

RFA On Role Of Nutrients In Cancer Prevention

June 3, 1983

NCI, IOM Called To Congress to Explain Divergent Positions On Minority Research

January 29, 1999

In Brief: Duke’s Gary Lyman to Co-Direct Fred Hutch Outcomes Research

January 10, 2014